Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Conatus

Conactus logoConatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.

 

Gary Burgess 

Gary Burgess is Senior Vice President and Chief Medical Officer for Conatus Pharmaceuticals. He has over 14 years of experience in the pharmaceutical industry and oversees all of the clinical development activities at Conatus. He has worked for a number of years in the area of infectious disease and liver fibrosis and is an experienced leader and drug developer across all phases of drug development. 

In this section

The Bio-medical Research Council (BRC), a part of the Oxford Hospital Radcliffe Trust (OHRT), funds research and many of our staff are involved in BRC research.

Our research is funded from a variety of funders. Their support allows our research to focus on the basic and clinical research domains to accelerate knowledge translation from the bedside to the bench, and back again.